Table 2.

Health questions (those marked with an asterisk* did not have sufficient evidence within the source recommendations and were included in the SLR)

Efficacy/adverse events of drug treatment

1. What are the goals of therapy?

2. Assessments (history, physical, laboratory and radiological) of patients, including the presence of extra articular manifestations, to achieve goals of therapy

3. Efficacy of pharmacotherapy in all PsA domains and in the presence of extra articular manifestations

4. Safety of pharmacotherapy in PsA

5. Efficacy of combination therapy

6. Safety of combination therapy*

7. Frequency of laboratory monitoring*

8. Safety and efficacy of biosimilars and intended copies*

Recommendations for Rheumatologists with limited access to Dermatologists and vice versa*

1. Recommendations to rheumatologist/internists for treatment of psoriasis particularly those with limited access to support from dermatologists

2. Recommendations to dermatologists for treatment of psoriatic arthritis particularly those with limited access to support from rheumatologists?

3. Recommendations for combined multidisciplinary team

4. Availability of allied health and social support: social work, physiotherapy, occupational therapy

TB, HB/CV, HIV, and other infections

1. Screening for TB prior to therapy with bDMARDs*

2. Recommendations for the management of the increased risk of TB with bDMARDs in high TB endemic areas*

3. Recommendations on the management of infection with TB, HIV, and HB/CV in patients receiving bDMARDs*

4. Safety of combination of bDMARDs and csDMARDs (higher risk of TB, HIV, HB/CV, Chagas’ disease, leishmaniasis, leprosy)*

5. Screening and management of HB/CV, HIV, Chagas’ disease, leishmaniasis, leprosy*

Assessing comorbidities and CV risk

1. Considerations for treatment of patients with psoriatic arthritis and concomitant comorbidities*

bDMARDs biological DMARD, csDMARDs conventional synthetic DMARDs, such as methotrexate, sulfasalazine, or leflunomide; DMARDs disease-modifying anti-rheumatic drugs, HIV human immunodeficiency virus, HB/CV hepatitis B/C virus, PsA psoriatic arthritis, TB tuberculosis